Prosecution Insights
Last updated: April 19, 2026

Examiner: SHAMEEM, GOLAM M

Tech Center 1600 • Art Units: 1621 1622 1626

This examiner grants 87% of resolved cases

Performance Statistics

86.9%
Allow Rate
+26.9% vs TC avg
895
Total Applications
+15.9%
Interview Lift
774
Avg Prosecution Days
Based on 875 resolved cases, 2023–2026

Rejection Statute Breakdown

0.3%
§101 Eligibility
19.8%
§102 Novelty
4.9%
§103 Obviousness
23.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18250504 SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18079729 PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS Non-Final OA HOFFMANN-LA ROCHE INC.
18220079 METHOD FOR PREPARING CHIRAL NITRO DERIVATIVES USING ORGANIC CHIRAL CATALYST COMPOUNDS AND ECO-FRIENDLY SOLVENTS Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18209894 METHOD FOR PREPARING CHIRAL MALEIMIDE DERIVATIVES USING ORGANIC CHIRAL CATALYST COMPOUNDS AND ECO-FRIENDLY SOLVENTS Non-Final OA KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
18567076 ORGANOPOLYSILOXANE-MODIFIED CYCLODEXTRIN COMPOUND AND COSMETICS CONTAINING SAME Non-Final OA Shin-Etsu Chemical Co., Ltd.
18035337 COMPOSITIONS FOR INCREASING TISSUE REGENERATION AND DELAYING OR REDUCING GRANULOMA FORMATION Non-Final OA THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
18566736 METHODS OF TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH OPIATE WITHDRAWAL OR OPIATE RELAPSE Non-Final OA Proniras Corporation
18284735 PROCESS FOR PREPARING CHLORANTRANILIPROLE Non-Final OA Gharda Chemicals Limited
18281038 ANTI-VIRAL COMPOUNDS Non-Final OA INFEX Therapeutics Limited
18243095 PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE Non-Final OA PTC THERAPEUTICS, INC.
18273476 SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME Non-Final OA Rappta Therapeutics Oy
17694902 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS Final Rejection BIAL - PORTELA & CA, S.A.
18252300 PREPARATION METHOD FOR CANNFLAVIN COMPOUNDS Non-Final OA DEYI PHARMACEUTICAL LTD.
18143793 PROCESS FOR THE PRODUCTION OF LEVETIRACETAM AND INTERMEDIATE THEREOF Non-Final OA Suzhou BrightHope Pharmatech Co., Ltd
17780083 Novel Quercetin Redox Derivative And Use Thereof As BET Inhibitor Non-Final OA Benobio Co., Ltd.
17771758 TREATMENT OF CONDITIONS OF THE NERVOUS SYSTEM Final Rejection The University of Leeds

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month